Search

Your search keyword '"De la Motte Rouge T"' showing total 348 results
Start Over Author "De la Motte Rouge T"
348 results on '"De la Motte Rouge T"'

3. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Author

Vergote, I., Ausems, M., Brasiuniene, B., Brenton, J., Büttner, R., Colombo, N., González-Martín, A., Harter, P., Lambrechts, D., Lorusso, D., Madry, R., Mirza, M.R., Pujol, P., Ray-Coquard, I., Abreu, M., Balboni, S., Banerjee, S., Barberis, M., Barretina Ginesta, M.P., Baurain, J.-F., Bignami, M., Bjorge, L., Blecharz, P., Bruchim, I., Capilna, M., Cerana, N., Cicchetti, A., Collins, D., Concin, N., D’Incalci, M., Davidson, B., de la Motte Rouge, T., De Iaco, P., Demirkiran, F., Denys, H., Doerk, T., Dorum, A., Ferrero, A., Fidalgo, A.P., Genuardi, M., Gladieff, L., Glasspool, R., Grimm, C., Gultekin, M., Hahnen, E., Hasenburg, A., Hegmane, A., Heinzelmann, V., Hogdall, E., Janavicius, R., Jarmalaite, S., Kalachand, R., Kaneva, R., Kilickap, S., Kocian, R., Kolencik, D., Kristeleit, R., Kryzhanivska, A., Leary, A., Lemley, B., Ligtenberg, M., López-Guerrero, J.A., Lord, C.J., Avall-Lundqvist, E., Maenpaa, J., Mahner, S., Marmé, F., Marth, C., McNeish, I., Merkelbach-Bruse, S., Mourits, M., Normanno, N., Oaknin, A., Ojamaa, K., Papdimitriou, C., Penault-Llorca, F., Perrone, A.M., Pignata, S., Pikarsky, E., Rouleau, E., Rubio, M., Sapino, A., Schmalfeldt, B., Sehouli, J., Shapira, R., Steffensen, K.D., Sukhin, V., Syrios, J., Szallasi, Z., Taskiran, C., Terzic, M., Tischkowitz, M., Toth, I., Van de Vijver, K., Vardar, M.A., Wasag, B., Wimberger, P., Witteveen, E., Brenton, J.D., and Ausems, M.G.E.M.

Published
2022
Full Text
View/download PDF

4. Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort

Author

Bringuier, M., Carton, M., Levy, C., Patsouris, A., Pasquier, D., Debled, M., Rigal, O., Jacot, W., Gonçalves, A., Desmoulins, I., De La Motte Rouge, T., Bachelot, T., Ferrero, J.-M., Eymard, J.-C., Ung, M., Mouret-Reynier, M.-A., Petit, T., Chevrot, M., Uwer, L., Courtinard, C., Frenel, J.-S., Vianzone, A., and Baldini, C.

Published
2022
Full Text
View/download PDF

5. 19P Long-term fatigue after treatments for non-epithelial ovarian cancer survivors

Author

Dubot, C., primary, Ray-Coquard, I.L., additional, Pautier, P., additional, Lequesne, J., additional, Renaud, T., additional, Selle, F., additional, Berton-Rigaud, D., additional, Frank, S., additional, De La Motte Rouge, T., additional, Kalbacher, E., additional, Gross, M. Provansal, additional, Blonz, C., additional, Orfeuvre, H., additional, Alexandre, J., additional, Augereau, P., additional, Kurtz, J.E., additional, Grellard, J-M., additional, Clarisse, B., additional, Gernier, F., additional, and Lobbedez, F. Joly, additional

Published
2024
Full Text
View/download PDF

7. Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Author

Bello Roufai, D., Gonçalves, A., De La Motte Rouge, T., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., Desmoulins, I., Tharin, Z., Renaud, E., Bertho, M., Benderra, M-A, Delaloge, S., Robert, L., Cottu, P., Pierga, J. Y., Loirat, D., Bertucci, A., Renouf, B., Bidard, F. C., and Lerebours, F.

Published
2023
Full Text
View/download PDF

8. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

Author

Derquin, F., Floquet, A., Hardy-Bessard, A.C., Edeline, J., Lotz, J.P., Alexandre, J., Pautier, P., Angeles, M.A., Delanoy, N., Lefeuvre-Plesse, C., Cancel, M., Treilleux, I., Augereau, P., Lavoue, V., Kalbacher, E., Berton Rigaud, D., Selle, F., Nadeau, C., Gantzer, J., Joly, F., Guillemet, C., Pomel, C., Favier, L., Abdeddaim, C., Venat-Bouvet, L., Provansal, M., Fabbro, M., Kaminsky, M.C., Lortholary, A., Lecuru, F., Coquard, I. Ray, and de La Motte Rouge, T.

Published
2020
Full Text
View/download PDF

9. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study

Author

Lenck, C., Chopin, N., Gouy, S., Bonsang-Kitzis, H., Martinez-Gomez, C., Radosevic-Robin, N., Martin, S., Lefeuvre-plesse, C., Lambaudie, E., Leblanc, E., Guyon, F., Classe, J.-M., Ramanah, R., Beurrier, F., Angeles, M.A., Pomel, C., Joly, F., de la Motte Rouge, T., Provansal, M., Lesoin, A., Floquet, A., Berton, D., Kalbacher, E., Chakiba, C., Meeus, P., Selle, F., Treilleux, I., Lecuru, F., Pautier, P., and Ray-Coquard, I.

Published
2020
Full Text
View/download PDF

10. Tumeurs frontières de l’ovaire. Recommandations pour la pratique clinique du CNGOF – Texte court

Author

Bourdel, N., Huchon, C., Cendos, A.W., Azaïs, H., Bendifallah, S., Bolze, P.A., Brun, J.L., Canlorbe, G., Chauvet, P., Chéreau, E., Courbiere, B., De La Motte Rouge, T., Devouassoux-Shisheboran, M., Eymerit-Morin, C., Fauvet, R., Gauroy, E., Gauthier, T., Grynberg, M., Koskas, M., Larouzee, E., Lecointre, L., Levêque, J., Margueritte, F., Mathieu D’argent, E., Nyangoh-Timoh, K., Ouldamer, L., Raad, J., Raimond, E., Ramanah, R., Rolland, L., Rousset, P., Rousset-Jablonski, C., Thomassin-Naggara, I., Uzan, C., Zilliox, M., and Daraï, E.

Published
2020
Full Text
View/download PDF

13. 21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE)

Author

Bertucci, A., primary, Maby, P., additional, Rochigneux, P., additional, Legrand, F., additional, Cropet, C., additional, Frenel, J-S., additional, Le Tourneau, C., additional, Hervieu, A., additional, Coquan, E., additional, De La Motte Rouge, T., additional, Saada, E.B., additional, Lavaud, P., additional, Ben-Amara, A., additional, Rouvière, M-S., additional, Grassi, P., additional, Gorvel, L., additional, Goncalves, A., additional, Olive, D., additional, and Chrétien, A-S., additional

Published
2023
Full Text
View/download PDF

14. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)

Author

Lavoue, V., Huchon, C., Akladios, C., Alfonsi, P., Bakrin, N., Ballester, M., Bendifallah, S., Bolze, P.A., Bonnet, F., Bourgin, C., Chabbert-Buffet, N., Collinet, P., Courbiere, B., De la motte rouge, T., Devouassoux-Shisheboran, M., Falandry, C., Ferron, G., Fournier, L., Gladieff, L., Golfier, F, Gouy, S., Guyon, F., Lambaudie, E, Leary, A., Lecuru, F., Lefrere-Belda, M.A., Leblanc, E., Lemoine, A, Narducci, F., Ouldamer, L., Pautier, P., Planchamp, F., Pouget, N., Ray-Coquard, I., Rousset-Jablonski, C., Senechal-Davin, C., Touboul, C., Thomassin-Naggara, I., Uzan, C., You, B., and Daraï, E.

Published
2019
Full Text
View/download PDF

15. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology

Author

Lavoue, V., Huchon, C., Akladios, C., Alfonsi, P., Bakrin, N., Ballester, M., Bendifallah, S., Bolze, P.A., Bonnet, F., Bourgin, C., Chabbert-Buffet, N., Collinet, P., Courbiere, B., De la motte rouge, T., Devouassoux-Shisheboran, M., Falandry, C., Ferron, G., Fournier, L., Gladieff, L., Golfier, F., Gouy, S., Guyon, F., Lambaudie, E., Leary, A., Lecuru, F., Lefrere-Belda, M.A., Leblanc, E., Lemoine, A., Narducci, F., Ouldamer, L., Pautier, P., Planchamp, F., Pouget, N., Ray-Coquard, I., Rousset-Jablonski, C., Senechal-Davin, C., Touboul, C., Thomassin-Naggara, I., Uzan, C., You, B., and Daraï, E.

Published
2019
Full Text
View/download PDF

16. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa

Author

Lavoue, V., Huchon, C., Akladios, C., Alfonsi, P., Bakrin, N., Ballester, M., Bendifallah, S., Bolze, P.A., Bonnet, F., Bourgin, C., Chabbert-Buffet, N., Collinet, P., Courbiere, B., De la motte rouge, T., Devouassoux-Shisheboran, M., Falandry, C., Ferron, G., Fournier, L., Gladieff, L., Golfier, F., Gouy, S., Guyon, F., Lambaudie, E., Leary, A., Lecuru, F., Lefrere-Belda, M.A., Leblanc, E., Lemoine, A., Narducci, F., Ouldamer, L., Pautier, P., Planchamp, F., Pouget, N., Ray-Coquard, I., Rousset-Jablonski, C., Senechal-Davin, C., Touboul, C., Thomassin-Naggara, I., Uzan, C., You, B., and Daraï, E.

Published
2019
Full Text
View/download PDF

18. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Author

Vergote, I, Gonzalez-Martin, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M, Brasiuniene, B, Madry, R, Brenton, J, Ausems, M, Buttner, R, Lambrechts, D, Abreu, M, Balboni, S, Banerjee, S, Barberis, M, Barretina Ginesta, M, Baurain, J, Bignami, M, Bjorge, L, Blecharz, P, Bruchim, I, Capilna, M, Cerana, N, Cicchetti, A, Collins, D, Concin, N, D'Incalci, M, Davidson, B, de la Motte Rouge, T, De Iaco, P, Demirkiran, F, Denys, H, Doerk, T, Dorum, A, Ferrero, A, Fidalgo, A, Genuardi, M, Gladieff, L, Glasspool, R, Grimm, C, Gultekin, M, Hahnen, E, Hasenburg, A, Hegmane, A, Heinzelmann, V, Hogdall, E, Janavicius, R, Jarmalaite, S, Kalachand, R, Kaneva, R, Kilickap, S, Kocian, R, Kolencik, D, Kristeleit, R, Kryzhanivska, A, Leary, A, Lemley, B, Ligtenberg, M, Lopez-Guerrero, J, Lord, C, Avall-Lundqvist, E, Maenpaa, J, Mahner, S, Marme, F, Marth, C, Mcneish, I, Merkelbach-Bruse, S, Mourits, M, Normanno, N, Oaknin, A, Ojamaa, K, Papdimitriou, C, Penault-Llorca, F, Perrone, A, Pignata, S, Pikarsky, E, Rouleau, E, Rubio, M, Sapino, A, Schmalfeldt, B, Sehouli, J, Shapira, R, Steffensen, K, Sukhin, V, Syrios, J, Szallasi, Z, Taskiran, C, Terzic, M, Tischkowitz, M, Toth, I, Van de Vijver, K, Vardar, M, Wasag, B, Wimberger, P, Witteveen, E, Vergote I., Gonzalez-Martin A., Ray-Coquard I., Harter P., Colombo N., Pujol P., Lorusso D., Mirza M. R., Brasiuniene B., Madry R., Brenton J. D., Ausems M. G. E. M., Buttner R., Lambrechts D., Ausems M., Brenton J., Abreu M., Balboni S., Banerjee S., Barberis M., Barretina Ginesta M. P., Baurain J. -F., Bignami M., Bjorge L., Blecharz P., Bruchim I., Capilna M., Cerana N., Cicchetti A., Collins D., Concin N., D'Incalci M., Davidson B., de la Motte Rouge T., De Iaco P., Demirkiran F., Denys H., Doerk T., Dorum A., Ferrero A., Fidalgo A. P., Genuardi M., Gladieff L., Glasspool R., Grimm C., Gultekin M., Hahnen E., Hasenburg A., Hegmane A., Heinzelmann V., Hogdall E., Janavicius R., Jarmalaite S., Kalachand R., Kaneva R., Kilickap S., Kocian R., Kolencik D., Kristeleit R., Kryzhanivska A., Leary A., Lemley B., Ligtenberg M., Lopez-Guerrero J. A., Lord C. J., Avall-Lundqvist E., Maenpaa J., Mahner S., Marme F., Marth C., McNeish I., Merkelbach-Bruse S., Mourits M., Normanno N., Oaknin A., Ojamaa K., Papdimitriou C., Penault-Llorca F., Perrone A. M., Pignata S., Pikarsky E., Rouleau E., Rubio M., Sapino A., Schmalfeldt B., Sehouli J., Shapira R., Steffensen K. D., Sukhin V., Syrios J., Szallasi Z., Taskiran C., Terzic M., Tischkowitz M., Toth I., Van de Vijver K., Vardar M. A., Wasag B., Wimberger P., Witteveen E., Vergote, I, Gonzalez-Martin, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M, Brasiuniene, B, Madry, R, Brenton, J, Ausems, M, Buttner, R, Lambrechts, D, Abreu, M, Balboni, S, Banerjee, S, Barberis, M, Barretina Ginesta, M, Baurain, J, Bignami, M, Bjorge, L, Blecharz, P, Bruchim, I, Capilna, M, Cerana, N, Cicchetti, A, Collins, D, Concin, N, D'Incalci, M, Davidson, B, de la Motte Rouge, T, De Iaco, P, Demirkiran, F, Denys, H, Doerk, T, Dorum, A, Ferrero, A, Fidalgo, A, Genuardi, M, Gladieff, L, Glasspool, R, Grimm, C, Gultekin, M, Hahnen, E, Hasenburg, A, Hegmane, A, Heinzelmann, V, Hogdall, E, Janavicius, R, Jarmalaite, S, Kalachand, R, Kaneva, R, Kilickap, S, Kocian, R, Kolencik, D, Kristeleit, R, Kryzhanivska, A, Leary, A, Lemley, B, Ligtenberg, M, Lopez-Guerrero, J, Lord, C, Avall-Lundqvist, E, Maenpaa, J, Mahner, S, Marme, F, Marth, C, Mcneish, I, Merkelbach-Bruse, S, Mourits, M, Normanno, N, Oaknin, A, Ojamaa, K, Papdimitriou, C, Penault-Llorca, F, Perrone, A, Pignata, S, Pikarsky, E, Rouleau, E, Rubio, M, Sapino, A, Schmalfeldt, B, Sehouli, J, Shapira, R, Steffensen, K, Sukhin, V, Syrios, J, Szallasi, Z, Taskiran, C, Terzic, M, Tischkowitz, M, Toth, I, Van de Vijver, K, Vardar, M, Wasag, B, Wimberger, P, Witteveen, E, Vergote I., Gonzalez-Martin A., Ray-Coquard I., Harter P., Colombo N., Pujol P., Lorusso D., Mirza M. R., Brasiuniene B., Madry R., Brenton J. D., Ausems M. G. E. M., Buttner R., Lambrechts D., Ausems M., Brenton J., Abreu M., Balboni S., Banerjee S., Barberis M., Barretina Ginesta M. P., Baurain J. -F., Bignami M., Bjorge L., Blecharz P., Bruchim I., Capilna M., Cerana N., Cicchetti A., Collins D., Concin N., D'Incalci M., Davidson B., de la Motte Rouge T., De Iaco P., Demirkiran F., Denys H., Doerk T., Dorum A., Ferrero A., Fidalgo A. P., Genuardi M., Gladieff L., Glasspool R., Grimm C., Gultekin M., Hahnen E., Hasenburg A., Hegmane A., Heinzelmann V., Hogdall E., Janavicius R., Jarmalaite S., Kalachand R., Kaneva R., Kilickap S., Kocian R., Kolencik D., Kristeleit R., Kryzhanivska A., Leary A., Lemley B., Ligtenberg M., Lopez-Guerrero J. A., Lord C. J., Avall-Lundqvist E., Maenpaa J., Mahner S., Marme F., Marth C., McNeish I., Merkelbach-Bruse S., Mourits M., Normanno N., Oaknin A., Ojamaa K., Papdimitriou C., Penault-Llorca F., Perrone A. M., Pignata S., Pikarsky E., Rouleau E., Rubio M., Sapino A., Schmalfeldt B., Sehouli J., Shapira R., Steffensen K. D., Sukhin V., Syrios J., Szallasi Z., Taskiran C., Terzic M., Tischkowitz M., Toth I., Van de Vijver K., Vardar M. A., Wasag B., Wimberger P., and Witteveen E.

Abstract

Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. Design: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts’ consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. Conclusion: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR de

Published
2022

19. NATURAL HISTORY OF PATIENTS WITH BRCA-MUTATED HIGH GRADE EPITHELIAL OVARIAN CANCER (HGEOC) BEFORE THE ERA OF PARP INHIBITORS MAINTENANCE IN 1ST LINE TREATMENT: EP967

Author

Romeo, C, Meeus, P, Rodrigues, M, Leblanc, E, Floquet, A, Pautier, P, Marchal, F, Provansal, M, Campion, L, Causeret, S, Gourgou, S, Ray-Coquard, I, Classe, J-M, Pomel, C, De La Motte Rouge, T, Barranger, E, Savoye, A M, Guillemet, C, Gladieff, L, Petit, T, Rouzier, R, Labreveux, C, Courtinard, C, and Joly, F

Published
2019
Full Text
View/download PDF

20. HOW THE CONFORMITY OF SURGICAL PRACTICE WITH THE NATIONAL GUIDELINES IMPROVED THE QUALITY OF MANAGEMENT OF OVARIAN GRANULOSA CELL TUMORS (GCT)? A TMRG AND GINECO GROUP STUDY: EP1225

Author

Lenck, C, Chopin, N, Gouy, S, Kitzis, Bonsang H, Gomez, Martinez C, Radosevic-Robin, N, Martin, S, Lefeuvre-Plesse, C, Lambaudies, E, Leblanc, E, Guyon, F, Classe, J-M, Ramanah, R, Beurrier, F, Angeles-Fite, M, Pomel, C, Joly, F, De La Motte Rouge, T, Provansal, M, Lesoin, A, Floquet, A, Berton-Rigaud, D, Kalbacher, E, Meus, P, Selle, F, Treilleux, I, Lecuru, F, Pautier, P, and Ray-Coquard, I

Published
2019
Full Text
View/download PDF

21. 19P Long term sexual disorders among rare ovarian cancer survivors: The national GINECO case-control Vivrovaire Rare Tumors study

Author

Dubot, C., primary, Joly Lobbedez, F., additional, Ray Coquard, I.L., additional, Floquet, A., additional, Lefevre Arbogast, S., additional, Selle, F., additional, Berton-Rigaud, D., additional, Frank, S., additional, De La Motte Rouge, T., additional, Kalbacher, E., additional, Provansal Gross, M., additional, Lortholary, A., additional, Orfeuvre, H., additional, Alexandre, J., additional, Augereau, P., additional, Nadeau, C., additional, Kurtz, J.E., additional, Grellard, J-M., additional, Pautier, P., additional, and Gernier, F., additional

Published
2023
Full Text
View/download PDF

22. 13O Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients: A TMRG and GINECO group study

Author

Hanvic, B., primary, Lecuru, F., additional, Vanacker, H., additional, Pautier, P., additional, Narducci, F., additional, Cherifi, F., additional, Floquet, A., additional, Angeles, M.A., additional, Berton-Rigaud, D., additional, Pomel, C., additional, Kalbacher, E., additional, Provansal Gross, M., additional, Fernandez, Y., additional, De La Motte Rouge, T., additional, Selle, F., additional, Meeus, P., additional, Genestie, C., additional, Salleron, J., additional, and Ray-Coquard, I.L., additional

Published
2023
Full Text
View/download PDF

23. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Author

Bello Roufai, D., primary, Gonçalves, A., additional, De La Motte Rouge, T., additional, Akla, S., additional, Blonz, C., additional, Grenier, J., additional, Gligorov, J., additional, Saghatchian, M., additional, Bailleux, C., additional, Simon, H., additional, Desmoulins, I., additional, Tharin, Z., additional, Renaud, E., additional, Bertho, M., additional, Benderra, M-A, additional, Delaloge, S., additional, Robert, L., additional, Cottu, P., additional, Pierga, J. Y., additional, Loirat, D., additional, Bertucci, A., additional, Renouf, B., additional, Bidard, F. C., additional, and Lerebours, F., additional

Published
2023
Full Text
View/download PDF

24. EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial

Author

Perrier, L, primary, Tredan, O, additional, Morelle, M, additional, Penel, N, additional, Fournel, P, additional, Greillier, L, additional, Ghiringhelli, F, additional, Tosi, D, additional, Bertucci, F, additional, Campone, M, additional, Delord, JP, additional, Pouessel, D, additional, Garin, G, additional, Chabaud, S, additional, Gomez-Roca, C, additional, Pannier, D, additional, Brahmi, M, additional, Fabbro, M, additional, Garcia, ME, additional, Ray-Coquard, I, additional, Viala, M, additional, Italiano, A, additional, Cassier, P, additional, Dufresne, A, additional, Attignon, V, additional, Treilleux, I, additional, Viari, A, additional, de la Motte Rouge, T, additional, Durando, X, additional, Perol, D, additional, and Blay, JY, additional

Published
2022
Full Text
View/download PDF

25. 144P Development of a 6-color multiplex crystal digital PCR assay for the simultaneous detection of ESR1 and PIK3CA mutations in the plasma of metastatic breast cancer patients

Author

Corné, J., primary, Quillien, V., additional, Godey, F., additional, Le Du, F., additional, Robert, L., additional, Bourien, H., additional, Brunot, A., additional, Crouzet, L., additional, Perrin, C., additional, Lefeuvre-Plesse, C., additional, Dieras, V.C., additional, and De La Motte Rouge, T., additional

Published
2022
Full Text
View/download PDF

26. 478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study

Author

Hervieu, A., primary, Guigay, J., additional, Borcoman, E., additional, Lavaud, P., additional, Coquan, E., additional, Frenel, J-S., additional, De La Motte Rouge, T., additional, Augereau, P., additional, Cropet, C., additional, Legrand, F., additional, and Goncalves, A., additional

Published
2022
Full Text
View/download PDF

27. 553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the French cohort temporary authorization of use (ATU)

Author

Rodrigues, M.J., primary, Eberst, L., additional, Follana, P., additional, Brunel, V., additional, Gauthier, L., additional, Jacquemin, V.J., additional, Tessier, C., additional, El Mouaddin, N., additional, Boudier, P., additional, Fiteni, F., additional, Angeli, E., additional, Roche, S., additional, Bonnet, I., additional, Deldycke, C., additional, Delanoy, N., additional, Sabatier, R., additional, Flippot, R., additional, and De La Motte Rouge, T., additional

Published
2022
Full Text
View/download PDF

28. 596P CA125 longitudinal decline kinetic is complementary to BRCA testing in first-line high grade serous ovarian carcinoma (HGSOC) patients (pts)

Author

Becker, O., primary, Chevrier, M., additional, Gladieff, L., additional, Joly Lobbedez, F., additional, Ray-Coquard, I.L., additional, Floquet, A., additional, Pomel, C., additional, Costaz, H., additional, Pautier, P., additional, De La Motte Rouge, T., additional, Sabatier, R., additional, Classe, J-M., additional, Leblanc, E., additional, Marchal, F., additional, Colombo, P-E., additional, Barranger, E., additional, Colomban, O., additional, Bosquet, L., additional, You, B., additional, and Rodrigues, M.J., additional

Published
2022
Full Text
View/download PDF

29. 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?

Author

Thibault, G., primary, Kfoury, M., additional, Lorusso, D., additional, Floquet, A., additional, Ventriglia, J., additional, Salaun, H., additional, Moubarak, M., additional, Rivoirard, R., additional, Polastro, L., additional, Favier, L., additional, You, B., additional, Berton-Rigaud, D., additional, De La Motte Rouge, T., additional, Mansi, L., additional, Abdeddaim, C., additional, Prulhiere, K., additional, Lancry Lecomte, L., additional, Provansal Gross, M., additional, Dalban, C., additional, and Ray-Coquard, I.L., additional

Published
2022
Full Text
View/download PDF

33. 712MO Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)

Author

Kurtz, J.E., Pujade-Lauraine, E., Oaknin, A., Belin, L., Grimm, C., Kocian, R., Denys, H., Rosengarten, O.S., Follana, P., Sehouli, J., Martinez-Garcia, J., Alexandre, J., Hardy-Bessard, A-C., Frenel, J-S., Sabatier, R., Gladieff, L., De La Motte Rouge, T., Lamichhane, N. Bonichon, Kalbacher, E., and Heitz, F.

Published
2024
Full Text
View/download PDF

34. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Poveda, A, Floquet, A, Ledermann, J, Asher, R, Penson, R, Oza, A, Korach, J, Huzarski, T, Pignata, S, Friedlander, M, Baldoni, A, Park-Simon, T, Tamura, K, Sonke, G, Lisyanskaya, A, Kim, J, Filho, E, Milenkova, T, Lowe, E, Rowe, P, Vergote, I, Pujade-Lauraine, E, Byrski, T, Pautier, P, Harter, P, Colombo, N, Scambia, G, Nicoletto, M, Nussey, F, Clamp, A, Poveda Velasco, A, Rodrigues, M, Lotz, J, Selle, F, Ray-Coquard, I, Provencher, D, Prat Aparicio, A, Vidal Boixader, L, Scott, C, Yunokawa, M, Medioni, J, Pecuchet, N, Dubot, C, De La Motte Rouge, T, Kaminsky, M, Weber, B, Lortholary, A, Parkinson, C, Williams, S, Banerjee, S, Cosin, J, Hoffman, J, Plante, M, Covens, A, Joly, F, Hirte, H, Amit, A, Matsumoto, K, Tjulandin, S, Hoon Kim, J, Gladieff, L, Sabbatini, R, O'Malley, D, Timmins, P, Kredentser, D, Lainez Milagro, N, Barretina Ginesta, M, Tibau Martorell, A, Gomez De Liano Lista, A, Ojeda Gonzalez, B, Mileshkin, L, Mandai, M, Boere, I, Ottevanger, P, Nam, J, Hamizi, S, Cognetti, F, Warshal, D, Dickson-Michelson, E, Kamelle, S, Mckenzie, N, Rodriguez, G, Armstrong, D, Chalas, E, Celano, P, Behbakht, K, Davidson, S, Welch, S, Helpman, L, Fishman, A, Bruchim, I, Sikorska, M, Slowinska, A, Rogowski, W, Bidzinski, M, Spiewankiewicz, B, Casado Herraez, A, Mendiola Fernandez, C, Gropp-Meier, M, Saito, T, Takehara, K, Enomoto, T, Watari, H, Choi, C, Kim, B, Weon Kim, J, Hegg, R, Poveda A., Floquet A., Ledermann J. A., Asher R., Penson R. T., Oza A. M., Korach J., Huzarski T., Pignata S., Friedlander M., Baldoni A., Park-Simon T. -W., Tamura K., Sonke G. S., Lisyanskaya A., Kim J. -H., Filho E. A., Milenkova T., Lowe E. S., Rowe P., Vergote I., Pujade-Lauraine E., Byrski T., Pautier P., Harter P., Colombo N., Scambia G., Nicoletto M., Nussey F., Clamp A., Penson R., Poveda Velasco A., Rodrigues M., Lotz J. -P., Selle F., Ray-Coquard I., Provencher D., Prat Aparicio A., Vidal Boixader L., Scott C., Yunokawa M., Medioni J., Pecuchet N., Dubot C., De La Motte Rouge T., Kaminsky M. -C., Weber B., Lortholary A., Parkinson C., Ledermann J., Williams S., Banerjee S., Cosin J., Hoffman J., Plante M., Covens A., Sonke G., Joly F., Hirte H., Amit A., Matsumoto K., Tjulandin S., Hoon Kim J., Gladieff L., Sabbatini R., O'Malley D., Timmins P., Kredentser D., Lainez Milagro N., Barretina Ginesta M. P., Tibau Martorell A., Gomez De Liano Lista A., Ojeda Gonzalez B., Mileshkin L., Mandai M., Boere I., Ottevanger P., Nam J. -H., Filho E., Hamizi S., Cognetti F., Warshal D., Dickson-Michelson E., Kamelle S., McKenzie N., Rodriguez G., Armstrong D., Chalas E., Celano P., Behbakht K., Davidson S., Welch S., Helpman L., Fishman A., Bruchim I., Sikorska M., Slowinska A., Rogowski W., Bidzinski M., Spiewankiewicz B., Casado Herraez A., Mendiola Fernandez C., Gropp-Meier M., Saito T., Takehara K., Enomoto T., Watari H., Choi C. H., Kim B. -G., Weon Kim J., Hegg R., Poveda, A, Floquet, A, Ledermann, J, Asher, R, Penson, R, Oza, A, Korach, J, Huzarski, T, Pignata, S, Friedlander, M, Baldoni, A, Park-Simon, T, Tamura, K, Sonke, G, Lisyanskaya, A, Kim, J, Filho, E, Milenkova, T, Lowe, E, Rowe, P, Vergote, I, Pujade-Lauraine, E, Byrski, T, Pautier, P, Harter, P, Colombo, N, Scambia, G, Nicoletto, M, Nussey, F, Clamp, A, Poveda Velasco, A, Rodrigues, M, Lotz, J, Selle, F, Ray-Coquard, I, Provencher, D, Prat Aparicio, A, Vidal Boixader, L, Scott, C, Yunokawa, M, Medioni, J, Pecuchet, N, Dubot, C, De La Motte Rouge, T, Kaminsky, M, Weber, B, Lortholary, A, Parkinson, C, Williams, S, Banerjee, S, Cosin, J, Hoffman, J, Plante, M, Covens, A, Joly, F, Hirte, H, Amit, A, Matsumoto, K, Tjulandin, S, Hoon Kim, J, Gladieff, L, Sabbatini, R, O'Malley, D, Timmins, P, Kredentser, D, Lainez Milagro, N, Barretina Ginesta, M, Tibau Martorell, A, Gomez De Liano Lista, A, Ojeda Gonzalez, B, Mileshkin, L, Mandai, M, Boere, I, Ottevanger, P, Nam, J, Hamizi, S, Cognetti, F, Warshal, D, Dickson-Michelson, E, Kamelle, S, Mckenzie, N, Rodriguez, G, Armstrong, D, Chalas, E, Celano, P, Behbakht, K, Davidson, S, Welch, S, Helpman, L, Fishman, A, Bruchim, I, Sikorska, M, Slowinska, A, Rogowski, W, Bidzinski, M, Spiewankiewicz, B, Casado Herraez, A, Mendiola Fernandez, C, Gropp-Meier, M, Saito, T, Takehara, K, Enomoto, T, Watari, H, Choi, C, Kim, B, Weon Kim, J, Hegg, R, Poveda A., Floquet A., Ledermann J. A., Asher R., Penson R. T., Oza A. M., Korach J., Huzarski T., Pignata S., Friedlander M., Baldoni A., Park-Simon T. -W., Tamura K., Sonke G. S., Lisyanskaya A., Kim J. -H., Filho E. A., Milenkova T., Lowe E. S., Rowe P., Vergote I., Pujade-Lauraine E., Byrski T., Pautier P., Harter P., Colombo N., Scambia G., Nicoletto M., Nussey F., Clamp A., Penson R., Poveda Velasco A., Rodrigues M., Lotz J. -P., Selle F., Ray-Coquard I., Provencher D., Prat Aparicio A., Vidal Boixader L., Scott C., Yunokawa M., Medioni J., Pecuchet N., Dubot C., De La Motte Rouge T., Kaminsky M. -C., Weber B., Lortholary A., Parkinson C., Ledermann J., Williams S., Banerjee S., Cosin J., Hoffman J., Plante M., Covens A., Sonke G., Joly F., Hirte H., Amit A., Matsumoto K., Tjulandin S., Hoon Kim J., Gladieff L., Sabbatini R., O'Malley D., Timmins P., Kredentser D., Lainez Milagro N., Barretina Ginesta M. P., Tibau Martorell A., Gomez De Liano Lista A., Ojeda Gonzalez B., Mileshkin L., Mandai M., Boere I., Ottevanger P., Nam J. -H., Filho E., Hamizi S., Cognetti F., Warshal D., Dickson-Michelson E., Kamelle S., McKenzie N., Rodriguez G., Armstrong D., Chalas E., Celano P., Behbakht K., Davidson S., Welch S., Helpman L., Fishman A., Bruchim I., Sikorska M., Slowinska A., Rogowski W., Bidzinski M., Spiewankiewicz B., Casado Herraez A., Mendiola Fernandez C., Gropp-Meier M., Saito T., Takehara K., Enomoto T., Watari H., Choi C. H., Kim B. -G., Weon Kim J., and Hegg R.

Abstract

Background: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. The aim of this final analysis is to investigate the effect of olaparib on overall survival. Methods: This double-blind, randomised, placebo-controlled, phase 3 trial was done across 123 medical centres in 16 countries. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status at baseline of 0–1, had histologically confirmed, relapsed, high-grade serous or high-grade endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, and had received two or more previous platinum regimens. Patients were randomly assigned (2:1) to receive olaparib tablets (300 mg in two 150 mg tablets twice daily) or matching placebo tablets using an interactive web or voice-response system. Stratification was by response to previous chemotherapy and length of platinum-free interval. Treatment assignment was masked to patients, treatment providers, and data assessors. The primary endpoint of progression-free survival has been reported previously. Overall survival was a key secondary endpoint and was analysed in all patients as randomly allocated. Safety was assessed in all patients who received at least one treatment dose. This trial is registered with ClinicalTrials.gov, NCT01874353, and is no longer recruiting patients. Findings: Between Sept 3, 2013 and Nov 21, 2014, 295 patients were enrolled. Patients were randomly assigned to receive either olaparib (n=196 [66%]) or placebo (n=99 [34%]). One patient, randomised in error, did not receive olaparib. Median follow-up was 65·7 months (IQR 63·6–69·3) with olaparib and 64·5 months (63·4–68·7) with placebo. Median overall survi

Published
2021

35. 44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

Author

Colombo, N., primary, Coleman, R.L., additional, Wu, X., additional, Kose, F., additional, Wenham, R., additional, Sebastianelli, A., additional, Hasegawa, K., additional, Zsiros, E., additional, De La Motte Rouge, T., additional, Bidzinski, M., additional, McNeish, I., additional, Sehouli, J., additional, Korach, J., additional, Debruyne, P.R., additional, Kim, J-W., additional, De Melo, A.C., additional, Peng, X., additional, Bogusz, A.M., additional, Yamada, K., additional, and Monk, B.J., additional

Published
2022
Full Text
View/download PDF

36. 167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial

Author

De La Motte Rouge, T., primary, Frenel, J-S., additional, Hardy-Bessard, A-C., additional, Bachelot, T., additional, Pistilli, B., additional, Delaloge, S., additional, Deiana, L., additional, Del Piano, F., additional, Genet, D., additional, Gardner, M., additional, Legouffe, E., additional, Levache, C.B., additional, Orfeuvre, H., additional, Valmar, C., additional, Venat, L., additional, Zannetti, A., additional, Le Scodan, R., additional, Dalenc, F., additional, Berger, D., additional, and Bidard, F.C., additional

Published
2022
Full Text
View/download PDF

38. 231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers

Author

Frenel, J-S., primary, Lusque, A., additional, Delaloge, S., additional, Ferrero, J-M., additional, Bachelot, T., additional, Desmoulins, I., additional, Levy, C., additional, Eymard, J-C., additional, Gonçalves, A., additional, Patsouris, A., additional, Reynier, M.A. Mouret, additional, Leheurteur, M., additional, Petit, T., additional, Cabel, L., additional, Uwer, L., additional, Debled, M., additional, Chevrot, M., additional, Mailliez, A., additional, Jacot, W., additional, and De La Motte Rouge, T., additional

Published
2021
Full Text
View/download PDF

40. 821TiP GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study

Author

De La Motte Rouge, T., primary, Berton, D., additional, Kalbacher, E., additional, Asselain, B., additional, Collard, O., additional, Rodrigues, M., additional, Lefevre, L. Bengrine, additional, Rouleau, E., additional, Nogues, C., additional, Just, P.A., additional, Morel, A., additional, Verriele, V., additional, Boidot, R., additional, Arnould, L., additional, Buisson, A., additional, Treilleux, I., additional, Callens, C., additional, Bataillon, G., additional, Becette, V., additional, and Pujade-Lauraine, E., additional

Published
2021
Full Text
View/download PDF

41. 817TiP GYNET study - Safety and efficacy of anti-netrin 1 (NP137) in combination with chemotherapy and/or pembrolizumab in patients (pts) with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: An adaptive multi-arms randomized phase I/II trial

Author

Ray-Coquard, I., primary, Cassier, P., additional, Chabaud, S., additional, Mehlen, P., additional, Bernet, A., additional, Le Bras, F., additional, Gheit, H., additional, Angel, C., additional, Mastier, C., additional, Ducarouge, B., additional, De La Motte Rouge, T., additional, Gladieff, L., additional, Floquet, A., additional, Fabbro, M., additional, Joly, F., additional, Provansal Gross, M., additional, Frenel, J-S., additional, Leary, A., additional, Perol, D., additional, and Blay, J-Y., additional

Published
2021
Full Text
View/download PDF

42. 727P Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study

Author

Leary, A., primary, De La Motte Rouge, T., additional, Lortholary, A., additional, Asselain, B., additional, Alexandre, J., additional, Floquet, A., additional, Savoye, A.M., additional, Chardin, L., additional, Delanoy, N., additional, Gavoille, C., additional, You, B., additional, D'Hondt, V., additional, Grenier, J., additional, Genestie, C., additional, and Pujade-Lauraine, E., additional

Published
2021
Full Text
View/download PDF

44. 746P Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France

Author

Rodrigues, M., primary, Joly, F., additional, Ray-Coquard, I.L., additional, Costaz, H., additional, Classe, J-M., additional, Floquet, A., additional, De La Motte Rouge, T., additional, Colombo, P-E., additional, Gross, M. Provansal, additional, Leblanc, E., additional, Pomel, C., additional, Marchal, F., additional, Barranger, E., additional, Savoye, A.M., additional, Guillemet, C., additional, Petit, T., additional, Pautier, P., additional, Rouzier, R., additional, Courtinard, C., additional, and Gladieff, L., additional

Published
2021
Full Text
View/download PDF

45. 314P Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane

Author

Vasseur, A., primary, Carton, M., additional, Guiu, S., additional, Augereau, P., additional, Uwer, L., additional, Mouret Reynier, M.A., additional, Levy, C., additional, Eymard, J-C., additional, Gonçalves, A., additional, Robert, M., additional, De La Motte Rouge, T., additional, Bachelot, T., additional, Petit, T., additional, Debled, M., additional, Grinda, T., additional, Desmoulins, I., additional, Vanlemmens, L., additional, Dalenc, F., additional, Simon, G., additional, and Cabel, L., additional

Published
2021
Full Text
View/download PDF

48. 796P Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database

Author

Papazyan, T., Martin, E., Pautier, P., Guerin-Charbonnel, C., Rowinski, E., Lecuru, F., Joly Lobbedez, F., De La Motte Rouge, T., Guillemet, C., Costaz, H., Sabatier, R., Barranger, E., Colombo, P-E., Marchal, F., Pomel, C., Savoye, A.M., Bosquet, L., Gladieff, L., Bourgin, C., and Frenel, J-S.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results